Street Calls of the Week
Investing.com - Canaccord Genuity raised its price target on Insulet Corporation (NASDAQ:PODD) to $399.00 from $353.00 on Monday, while maintaining a Buy rating on the insulin pump maker’s stock. According to InvestingPro data, the company currently trades at a high earnings multiple with a P/E ratio of 96, reflecting strong market confidence in its growth potential.
The research firm adjusted its model to reflect updated revenue guidance and commentary from recent investor conferences, slightly increasing its forward revenue estimates to $2.639 billion from $2.627 billion for 2025.
For 2026, Canaccord now projects Insulet’s revenue at $3.046 billion, up from its previous estimate of $3.033 billion, while incorporating 100 basis points of operating margin expansion in both 2025 and 2026.
Despite the revenue increases, Canaccord lowered its 2026 operating income estimate to $549.3 million from $561.0 million and reduced its earnings per share forecast to $5.74 from $6.09, citing updated net interest expense assumptions.
The firm maintained its positive thesis on Insulet, noting the company is "well positioned to win in the insulin pump market with its differentiated form factor and first mover advantage in the T2D market."
In other recent news, Insulet Corporation has been in the spotlight with several significant developments. The company has partnered with Pantone to introduce "Omnipod Mango," a new official color aimed at differentiating its brand. This vibrant hue represents the diabetes community and the freedom associated with Insulet’s tubeless insulin delivery system. In terms of financial insights, Truist Securities has reiterated its Buy rating with a price target of $365, while Oppenheimer has initiated coverage with an Outperform rating, also setting a $365 price target. Barclays has adjusted its price target for Insulet from $266 to $300, citing stronger sales projections as a key factor. On the leadership front, Insulet has announced a transition in its Chief Financial Officer position, with the current CFO staying on as a Senior Advisor to ensure a smooth transition. Additionally, Eric Benjamin has been appointed as the new Chief Operating Officer, where he will oversee growth and innovation strategies. These recent developments highlight Insulet’s ongoing efforts to expand its market presence and enhance its operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.